spacer
home > ebr > spring 2002 > preclinical and clinical evaluation of therapeutic vaccines - 21st-22nd january 2002, london
PUBLICATIONS
European Biopharmaceutical Review

Preclinical and Clinical Evaluation of Therapeutic Vaccines - 21st-22nd January 2002, London

Since as long ago as the 1890s, when William Coley used streptococcal cultures to treat patients with advanced sarcoma, it has been known that the immune system can be prompted to attack cancer cells. More recently, melanoma tumours in animals have been shown to regress when injected with modified autologous cancer cells primed to stimulate an immune response. And now, somewhat like the resurgence of interest surrounding recent therapeutic success with monoclonal antibodies, the concept of stimulating the immune system to recognise and destroy foreign or indeed tumour cells, so-called 'therapeutic vaccines', is, it seems, again in vogue.This kind of technology is distinct from normal vaccination in that the patient already has the disease or condition before the vaccine is given. For any number of reasons, the patient has not already responded to the disease-associated antigens - possibly because they are 'self'-antigens (on endogenous cells such as tumour cells), or they are hidden from the immune response by directly disrupting or affecting immune cell function (HIV).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Helen Abbott and Dr Keith Chidwick of Technomark Consulting Services Limited
spacer
Dr Helen Abbott
spacer
spacer
spacer
Dr Keith Chidwick
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment

The non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system
More info >>

White Papers

Challenges of Analytical Method Transfer in the Pharmaceutical Industry

RSSL

The development and validation of suitable analytical methods is a critical part of the overall drug-development life-cycle. For the majority of products, particularly those that are clinically successful, the transfer of the analytical method between laboratories will be required. This process is designed to verify that a given laboratory is capable of performing a test method for its intended purpose. This can be performed either internally (at the same company), or, with the on-going increasing trend in outsourcing, to an external Contract Research or Development organisation (CRO or CDO).
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement